Standard BioTools (LAB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$84.6M

Revenue (quarter)

$20.1M

Revenue growth (year over year)

−7.62%

Gross profit (trailing twelve months)

$42.7M

Gross margin

50.49%

Net income (trailing twelve months)

$84.9M

Net income (quarter)

−$26.8M

Net income growth (year over year)

+20.03%

Net margin

100.37%

Return on equity

17.61%

EPS (trailing twelve months)

$0.22

Book value per share

$1.38

P/E (trailing twelve months)

2.99

Price to book

0.47

Debt to assets

13.91%

Payout ratio

—

Dividend yield

—

• Is Standard BioTools (LAB) profitable?

  Yes. Standard BioTools earned $84.9M in net income over the trailing twelve months, a net margin of 100.37%.

• How much revenue does Standard BioTools (LAB) make?

  Standard BioTools generated $84.6M in revenue over the trailing twelve months, down 7.62% year over year.

• What is LAB's P/E ratio?

  Standard BioTools trades at 3.0 times trailing twelve-month earnings, on an EPS of $0.22.

• How do I buy stock in Standard BioTools (LAB)?

  LAB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.